A Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease

Trial Profile

A Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Mar 2018

At a glance

  • Drugs Pimavanserin (Primary)
  • Indications Aggression; Agitation
  • Focus Therapeutic Use
  • Sponsors Acadia Pharmaceuticals
  • Most Recent Events

    • 16 Mar 2018 Status changed from active, no longer recruiting to completed.
    • 05 Dec 2017 Planned number of patients changed from 432 to 120.
    • 05 Dec 2017 Planned End Date changed from 1 Jul 2019 to 1 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top